Company Description
Gain Therapeutics, Inc., a biotechnology company, develops novel small molecule therapeutics to treat diseases across various therapeutic areas in Switzerland, Spain, the United States, and Australia.
Its drug discovery platform Magellan discovers novel allosteric binding sites in a disease; identifies proprietary small molecules that bind these sites to modulate protein function; and treats the underlying cause of the disease.
The company’s lead drug candidate is GT-02287, which is currently in a Phase 1b study for the treatment of Parkinson’s disease with or without a GBA1 mutation.
It has various small molecule drug candidates, which are in the discovery, research, and preclinical stages for the treatment of dementia with Lewy bodies, Alzheimer's disease, and Gaucher’s disease, lysosomal storage disorders, metabolic disorders, and solid tumors.
Gain Therapeutics, Inc. was founded in 2017 and is based in Bethesda, Maryland.
| Country | United States |
| Founded | 2017 |
| IPO Date | Mar 18, 2021 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 25 |
| CEO | Gene Mack |
Contact Details
Address: 4800 Montgomery Lane, Suite 220 Bethesda, Maryland 20814 United States | |
| Phone | 301 500 1556 |
| Website | gaintherapeutics.com |
Stock Details
| Ticker Symbol | GANX |
| Exchange | NASDAQ |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| IPO Price | $11.00 |
| CIK Code | 0001819411 |
| CUSIP Number | 36269B105 |
| ISIN Number | US36269B1052 |
| Employer ID | 85-1726310 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Gene Mack M.B.A. | President, Chief Executive Officer and Director |
| Dr. Khalid Islam Ph.D. | Chairman and Founder |
| Gianluca Fuggetta | Senior Vice President of Finance and Principal Financial Officer |
| Dr. Terenzio Ignoni Pharm.D. | Senior Vice President of Technical Operations |
| Dr. Joanne Taylor Ph.D. | Senior Vice President of Research |
| Dr. Jonas Hannestad M.D., Ph.D. | Chief Medical Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Jul 17, 2025 | 424B5 | Filing |
| Jul 17, 2025 | 8-K | Current Report |
| Jul 15, 2025 | 424B5 | Filing |
| Jun 30, 2025 | 8-K | Current Report |
| Jun 24, 2025 | 8-K | Current Report |
| May 28, 2025 | S-3 | Registration statement under Securities Act of 1933 |
| May 14, 2025 | 10-Q | Quarterly Report |
| May 14, 2025 | 8-K | Current Report |
| Apr 29, 2025 | ARS | Filing |
| Apr 29, 2025 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material |